TVRD Tvardi Therapeutics, Inc.

CIK 0001346830 30 ready 8-Ks latest May 8, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 30

Latest filing May 8, 2026, 7:59 PM ET

Top materiality 0.90

Event mix other_material ×13 · m_and_a ×6 · earnings ×5

Sentiment 3 pos · 7 neg · 20 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for TVRD

Highest-materiality recent filing

Cara-Tvardi merger closes, new company renamed Tvardi Therapeutics (TVRD)

April 15, 2025, 7:59 PM ET M&A materiality 0.90 neutral item 2.01 item 1.01 item 5.02 item 9.01 item 3.03 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 item 8.01 ◈ executive_change ×12

Merger completed April 15, 2025: Merger Sub merged into Tvardi, which became a wholly owned subsidiary.
Post-merger ownership: pre-Cara holders ~15.4%, pre-Tvardi holders ~72.0%, Convertible Note holders ~12.5% fully diluted.

Read filing →

May 8, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026

Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.
March 31, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead

Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.
November 13, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026

Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.
October 14, 2025, 7:59 PM ET other material materiality 0.80 negative item 8.01 item 9.01

Tvardi Therapeutics Phase 2 IPF trial misses endpoints; no benefit from TTI-101

Trial did not meet goals; no statistically significant difference between TTI-101 and placebo on FVC change.
August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025

Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.
May 13, 2025, 7:59 PM ET other material materiality 0.70 negative item 2.01 item 9.01

Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists

Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.
May 13, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02 item 4.01 item 9.01

Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026

Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
April 15, 2025, 7:59 PM ET M&A materiality 0.90 neutral item 2.01 item 1.01 item 5.02 item 9.01 item 3.03 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 item 8.01 ◈ executive_change ×12

Cara-Tvardi merger closes, new company renamed Tvardi Therapeutics (TVRD)

Merger completed April 15, 2025: Merger Sub merged into Tvardi, which became a wholly owned subsidiary.
April 1, 2025, 7:59 PM ET M&A materiality 0.75 positive item 5.07 item 8.01 item 9.01

Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss

All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.
January 21, 2025, 6:59 PM ET M&A materiality 0.60 neutral item 7.01 item 9.01

Cara Therapeutics files investor presentation for proposed merger with Tvardi

Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.
January 17, 2025, 6:59 PM ET other material materiality 0.60 neutral item 8.01

Nasdaq bid price compliance regained; equity compliance deadline extended to May 19

Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.
December 30, 2024, 6:59 PM ET other material materiality 0.65 neutral item 5.03 item 9.01

Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M

Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
December 20, 2024, 6:59 PM ET M&A materiality 0.90 neutral item 9.01

Cara Therapeutics files amended 8-K to correct investor presentation for proposed merger with Tvardi Therapeutics

Merger agreement with Tvardi Therapeutics and merger sub was signed on December 17, 2024.
December 18, 2024, 6:59 PM ET M&A materiality 0.90 neutral item 1.01 item 5.01 item 5.02 item 8.01 item 9.01

Cara Therapeutics to Merge with Tvardi Therapeutics and Sell Difelikefalin Assets to CSL Vifor

Cara enters Merger Agreement with Tvardi; pre-Merger Cara holders will own ~15.25%, Tvardi holders ~12.54%, convertible note holders ~72.21% of combined company.
November 22, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 9.01

Cara Therapeutics gets Nasdaq deficiency for equity ($707K vs $2.5M min); also faces bid-price delisting risk

Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.
August 1, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

Cara Therapeutics gets Nasdaq extension to Jan 2025 to regain $1 bid price; stock moved to Capital Market

Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.
June 18, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.05

Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives

Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.
June 12, 2024, 7:59 PM ET other material materiality 0.85 negative item 7.01 item 8.01 item 9.01

Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study

Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.
June 7, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.03 item 5.07 item 9.01

CARA shareholders approve doubling authorized shares and authorize reverse stock split

Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.
May 13, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24

Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.